CD4 and breast carcinoma: Based on the GSE114082 datasets, we identified that the TILs with significant differences were M2 macrophages, M0 macrophages, gamma delta T cells, plasma cells, resting memory CD4 T cells, and resting mast cells in breast cancer tissues pre- or posttreated by trastuzumab.